Barbara Klencke
2017
In 2017, Barbara Klencke earned a total compensation of $675.2K as Chief Development Officer at ProNAi Therapeutics, a 55% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $154,350 |
|---|---|
| Option Awards | $77,157 |
| Salary | $441,000 |
| Other | $2,700 |
| Total | $675,207 |
Klencke received $441K in salary, accounting for 65% of the total pay in 2017.
Klencke also received $154.4K in non-equity incentive plan, $77.2K in option awards and $2.7K in other compensation.
Rankings
In 2017, Barbara Klencke's compensation ranked 10,769th out of 14,666 executives tracked by ExecPay. In other words, Klencke earned more than 26.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,769 out of 14,666 | 27th |
Division Manufacturing | 4,191 out of 5,768 | 27th |
Major group Chemicals And Allied Products | 1,498 out of 2,074 | 28th |
Industry group Drugs | 1,224 out of 1,730 | 29th |
Industry Pharmaceutical Preparations | 950 out of 1,329 | 29th |
Source: SEC filing on April 24, 2018.
Klencke's colleagues
We found two more compensation records of executives who worked with Barbara Klencke at ProNAi Therapeutics in 2017.